Health topic

Mild Cognitive Impairment

These are reviewed research connections, not a ranked list of remedies. An ingredient can appear here because evidence was uncertain, preclinical, or limited to a specific preparation and setting.

Ailment-to-evidence view

What the reviewed research points to

This order reflects the depth of the reviewed evidence, not which option works best or what anyone should take. Mixed and negative findings stay in the list because they can be more useful than a promising headline.

Substantial reviewed evidence Early signal

Lion's Mane

The placebo-controlled design is useful, but 15 people per arm and one cognitive scale cannot provide a stable or broadly generalizable estimate.

Studied form
Twelve 250 mg tablets per day, each containing 96% Yamabushitake dry powder, for 16 weeks
Outcome
Scores on a cognitive-function scale based on the Revised Hasegawa Dementia Scale during treatment and four weeks after stopping
Evidence
Double-blind, parallel-group, placebo-controlled randomized trial
See the evidence and cautions →
How this order is calculated

Evidence syntheses come before individual randomized trials, which come before early human and preclinical work. Sample-size bands add a small amount. Positive, mixed, negative, and safety-only directions do not change the depth score. Study independence is not yet scored, so overlapping reviews must not be counted as separate confirmation.

Connected ingredients

What appears in the current evidence map

Source-linked records

1 reviewed record

Randomized trial Early signal 30 Japanese adults aged 50 to 80 with mild cognitive impairment; 15 per group

Lion's Mane dry powder and mild cognitive impairment: small randomized trial

Thirty adults with mild cognitive impairment were randomized to Lion's Mane dry-powder tablets or placebo for 16 weeks. The Lion's Mane group had statistically higher cognitive-scale scores than placebo at weeks 8, 12, and 16, but the published abstract gives no effect size or confidence interval. Scores fell significantly during the four weeks after treatment stopped. This is an early human signal, not evidence that Lion's Mane prevents dementia or produces lasting benefit.

What was studied
Twelve 250 mg tablets per day, each containing 96% Yamabushitake dry powder, for 16 weeks
Setting
Studied alone
Why it ranks here
The placebo-controlled design is useful, but 15 people per arm and one cognitive scale cannot provide a stable or broadly generalizable estimate.
Limits and cautions
  • Only 30 participants were randomized, leaving the estimate vulnerable to chance and baseline imbalance.
  • The publisher abstract reports statistical significance but not the between-group effect size, variance, confidence interval, attrition, or allocation details; no numerical benefit claim is supportable from the accessible source.
  • Scores declined four weeks after stopping, so persistence of any effect was not established.
  • The study used one Japanese cognitive screening scale and one specific dry-powder tablet regimen; it does not establish equivalence to extracts, mycelium products, or other retail supplements.
  • PubMed lists the first author's affiliation as the Mushroom Laboratory of Hokuto Corporation. Affiliations for the other authors, funding sources, and conflict-of-interest disclosures could not be verified from the sources reviewed (the PubMed record and the accessible publisher abstract); this does not mean they are absent.

Lion's Mane products are not FDA-approved to prevent or treat mild cognitive impairment, dementia, or another medical condition.